



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **Lindsey Baden, M.D.**

Committee: **Antimicrobial Drugs Advisory Committee**

Meeting Date: **March 16, 2023**

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On March 16, 2023, the committee will discuss new drug application (NDA) 217188, for Paxlovid (nirmatrelvir and ritonavir co-packaged tablets) for oral use, submitted by Pfizer, Inc. The proposed indication is treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID 19, including hospitalization or death.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
Contract/grant	Employer’s research funded by National Heart, Lung, and Blood Institute (NHLBI)/Duke Clinical Research Institute (DCRI), unrelated entities	Dr. Baden is not aware of the funding amount being provided to Brigham and Women's Hospital

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/_____
Signature

_____2/23/2023_____
Date